These habits stimulate the bodys own GLP-1 production rather than mimicking the hormone
Similarly, Novo Nordisks weight loss drug has shown promising liver benefits in a new preclinical study, pointing to effects beyond just shedding pounds
In older male patients over 65 years old with diabetes and impaired physical performance, 250 mg NMN supplementation for 24 weeks was safe and tolerated and did not improve grip strength and walking speed [188]
For dual receptor agonists, trials provide measurable data on blood sugar control, weight loss, metabolic improvements, and potential side effects, guiding dosage and patient selection
[Sidebar discussion: is there a market to develop products and services for the longevity economy to meet the needs of people who are less affluent, older, etc
Fitness companies could develop evidence-based protocols tailored to GLP-1 users at different stages of treatment